BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Meissner EG. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis 2018;67:878-80. [PMID: 29718134 DOI: 10.1093/cid/ciy208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Righi E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World J Gastroenterol 2018; 24(38): 4311-4329 [PMID: 30344417 DOI: 10.3748/wjg.v24.i38.4311] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
3 Nobs SP, Tuganbaev T, Elinav E. Microbiome diurnal rhythmicity and its impact on host physiology and disease risk. EMBO Rep 2019;20:e47129. [PMID: 30877136 DOI: 10.15252/embr.201847129] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
4 Lu H, Chen L, Pan X, Yao Y, Zhang H, Zhu X, Lou X, Zhu C, Wang J, Li L, Wu Z. Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. Front Med (Lausanne) 2021;8:762930. [PMID: 34722597 DOI: 10.3389/fmed.2021.762930] [Reference Citation Analysis]
5 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
6 Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, Koris A, Vatai G. Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. Medicina (Kaunas) 2018;54:E18. [PMID: 30344249 DOI: 10.3390/medicina54020018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019;3:456-470. [PMID: 30976737 DOI: 10.1002/hep4.1331] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
9 Molinero N, Ruiz L, Sánchez B, Margolles A, Delgado S. Intestinal Bacteria Interplay With Bile and Cholesterol Metabolism: Implications on Host Physiology. Front Physiol 2019;10:185. [PMID: 30923502 DOI: 10.3389/fphys.2019.00185] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 23.3] [Reference Citation Analysis]
10 Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019;11:1. [PMID: 30675188 DOI: 10.1186/s13099-018-0281-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
11 Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. mSystems. 2020;5. [PMID: 32546668 DOI: 10.1128/msystems.00153-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
12 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
13 Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and Frailty in Liver Cirrhosis. Life (Basel) 2021;11:399. [PMID: 33925660 DOI: 10.3390/life11050399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
15 Liu YS, Li S, Wang XF, Xing T, Li JL, Zhu XD, Zhang L, Gao F. Microbiota populations and short-chain fatty acids production in cecum of immunosuppressed broilers consuming diets containing γ-irradiated Astragalus polysaccharides. Poult Sci 2021;100:273-82. [PMID: 33357691 DOI: 10.1016/j.psj.2020.09.089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
17 Guo J, Shi J, Wang H, Chen H, Liu S, Li J, Wang Y. Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study. Exp Ther Med 2019;17:4568-76. [PMID: 31186679 DOI: 10.3892/etm.2019.7502] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Philips CA, Augustine P, Yerol PK, Ramesh GN, Ahamed R, Rajesh S, George T, Kumbar S. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8:87-99. [PMID: 32274349 DOI: 10.14218/jcth.2019.00035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]